Post-TB lung disease (PTLD) is defined as evidence of chronic respiratory abnormality, with or without symptoms, and deficit lung function due to, at least in part, previous pulmonary TB (PTB). There has been an increase in the number of people who survive TB, but it has become evident that some individuals suffer from residual pulmonary pathology despite successful treatment, resulting in PTLD. The association of TB and the subsequent sequelae, particularly PTLD, has been under-recognized in the last five decades, but the high disease burden associated with the condition has, however, come under the spotlight in the last 10 years. PTLD’s contribution to TB-related morbidity remains largely unreported and unaccounted for. The underlying causes of PTLD are complex and poorly understood, with up to 50% of people developing chronic lung impairment after successful TB treatment, accounting for more than three times the mortality rate of the general population. In addition, our local data show that in patients who are in the post-TB stage, IL-1 was 83 times higher than the normal range, and IL-6 was 26 times higher. Whereas TNF-alpha was two times higher, and CRP was six times higher than the normal range for this biomarker. The lack of research to better understand post-TB lung disease must be addressed because if a pro-inflammatory state truly persists despite successful TB regimens, then these cytokines may contribute to the anomalies like cavitation, pulmonary vascular remodeling, pulmonary hypertension, and could later lead to right heart dysfunction and failure.